Human leukocyte antigen DR status and clinical features in Japanese patients with type 1 autoimmune hepatitis

Hepatology Research

Volumn 38, Issue 1, 2008, Pages 96-102

  Miyake, Yasuhiro ^a   Iwasaki, Yoshiaki ^a   Takaki, Akinobu ^a   Onishi, Toru ^b   Okamoto, Ryoichi ^c   Takaguchi, Kouichi ^d   Ikeda, Hiroshi ^e   Makino, Yasuhiro ^f   Kobashi, Haruhiko ^a   Sakaguchi, Kohsaku ^a   Shiratori, Yasushi ^a  

^a OKAYAMA UNIVERSITY   (Japan)

^b Mitoyo General Hospital   (Japan)

^c HIROSHIMA CITY HOSPITAL   (Japan)

^d KAGAWA PREFECTURAL CENTRAL HOSPITAL   (Japan)

^e KURASHIKI CENTRAL HOSPITAL   (Japan)

^f IWAKUNI NATIONAL HOSPITAL   (Japan)

Author keywords

Concurrent autoimmune disease; Human leukocyte antigen; Immunoglobulin G; Type1 autoimmune hepatitis

Indexed keywords

ALANINE AMINOTRANSFERASE; AZATHIOPRINE; CORTICOSTEROID; HLA DR ANTIGEN; HLA DR2 ANTIGEN; HLA DR4ANTIGEN; IMMUNOGLOBULIN G; PREDNISOLONE; UNCLASSIFIED DRUG; URSODEOXYCHOLIC ACID;

ADOLESCENT; ADULT; AGED; ANTIGEN DETECTION; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNE HEPATITIS; CLINICAL FEATURE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DIABETES MELLITUS; DNA HYBRIDIZATION; ETHNIC DIFFERENCE; FEMALE; GENETIC SCREENING; HUMAN; HUMAN TISSUE; IMMUNOGLOBULIN BLOOD LEVEL; JAPAN; LIVER BIOPSY; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NUCLEOTIDE SEQUENCE; OSTEOPOROSIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; SUPERINFECTION; TREATMENT DURATION;

EID: 36548999877     PISSN: 13866346     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2007.00204.x     Document Type: Article

References (13)

1. Manns MP, Strassburg CP. Autoimmune hepatitis: Clinical challenges. Gastroenterology 2001; 120: 1502-17.
2. Czaja AJ, Doherty DG, Donaldson PT. Genetic bases of autoimmune hepatitis. Dig Dis Sci 2002; 47: 2139-50.
3. Czaja AJ, Carpenter HA, Moore SB. Clinical and HLA phenotypes of type 1 autoimmune hepatitis in North American patients outside DR3 and DR4. Liver Int 2006; 26: 552-8.
4. Bittencourt PL, Goldberg AC, Cancado EL et al. Genetic heterogeneity in susceptibility to autoimmune hepatitis types 1 and 2. Am J Gastroenterol 1999; 94: 1906-13.
5. Czaja AJ, Freese DK, American Association for the Study of Liver Disease. Diagnosis and treatment of autoimmune hepatitis. Hepatology 2002; 36: 479-97.
6. Toda G, Zeniya M, Watanabe F et al. Present status of autoimmune hepatitis in Japan - correlating the characteristics with international criteria in an area with a high rate of HCV infection. Japanese National Study Group of Autoimmune Hepatitis. J Hepatol 1997; 26: 1207-12.
7. Yoshizawa K, Ota M, Katsuyama Y et al. Genetic analysis of the HLA region of Japanese patients with type 1 autoimmune hepatitis. J Hepatol 2005; 42: 578-84.
8. Alvarez F, Berg PA, Bianchi FB et al. International Autoimmune Hepatitis Group Report: Review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999; 31: 929-38.
9. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. Classification of chronic hepatitis: Diagnosis, grading and staging. Hepatology 1994; 19: 1513-20.
10. Czaja AJ, Donaldson PT. Gender effects and synergisms with histocompatibility leukocyte antigens in type 1 autoimmune hepatitis. Am J Gastroenterol 2002; 97: 2051-7.
11. Qiu DK, Ma X. Relationship between human leukocyte antigen-DRB1 and autoimmune hepatitis type I in Chinese patients. J Gastroenterol Hepatol 2003; 18: 63-7.
12. Honda K, Tamai H, Morita T, Kuma K, Nishimura Y, Sasazuki T. Hashimoto's thyroiditis and HLA in Japanese. J Clin Endocrinol Metab 1989; 69: 1268-73.
13. Czaja AJ, Carpenter HA, Santrach PJ, Moore SB. Significance of HLA DR4 in type 1 autoimmune hepatitis. Gastroenterology 1993; 105: 1502-7.